Valuation: Jupiter Neurosciences, Inc.

Market Cap 3.36M 2.99M 2.79M 2.54M 4.79M 323M 4.84M 33.74M 13.08M 165M 12.62M 12.35M 530M P/E 2024
-126x
P/E 2025 -4.08x
Enterprise Value 4.89M 4.35M 4.06M 3.7M 6.97M 470M 7.04M 49.1M 19.02M 240M 18.37M 17.97M 772M EV / Sales 2024
-
EV / Sales 2025 1,681x
Free-Float
68.41%
Yield 2024 *
-
Yield 2025 -
1 day+2.00%
1 week-4.49%
Current month+4.51%
1 month-21.78%
3 months-84.75%
6 months-90.78%
Current year-96.67%
1 week 2.35
Extreme 2.35
2.67
1 month 2.35
Extreme 2.35
3.68
Current year 2.35
Extreme 2.35
81.75
1 year 2.35
Extreme 2.35
135.75
3 years 2.35
Extreme 2.35
1,463.25
5 years 2.35
Extreme 2.35
1,463.25
10 years 2.35
Extreme 2.35
1,463.25
Manager TitleAgeSince
Chief Administrative Officer 34 2015-12-31
Chief Tech/Sci/R&D Officer 71 2015-12-31
Chief Executive Officer 74 2015-12-31
Director TitleAgeSince
Chairman 74 2015-12-31
Director/Board Member 71 2015-12-31
Director/Board Member 48 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Free

Director

472,222 0.9792%
6/29/26 Free

Director

536,428 1.1124%
6/2/26 Free

Director

100,000 0.2756%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%-4.49%-97.91% - 3.36M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.00%-0.98%+37.58%+128.54% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2024 2025
Net sales - 21.8K 19.37K 18.07K 16.47K 31.07K 2.1M 31.36K 219K 84.76K 1.07M 81.83K 80.06K 3.44M
Net income -2.44M -2.17M -2.02M -1.84M -3.48M -235M -3.51M -24.48M -9.49M -120M -9.16M -8.96M -385M -8.64M -7.68M -7.17M -6.53M -12.32M -831M -12.44M -86.76M -33.62M -425M -32.46M -31.75M -1.36B
Net Debt -3.55M -3.16M -2.95M -2.68M -5.06M -341M -5.11M -35.64M -13.81M -175M -13.34M -13.05M -560M 1.53M 1.36M 1.27M 1.16M 2.18M 147M 2.2M 15.35M 5.95M 75.19M 5.74M 5.62M 241M
Logo Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.
Employees
-
Date Price Change Volume
26-10-02 US$2.550 +2.00% 11,992
26-10-01 US$2.500 +2.46% 13,378
26-09-30 US$2.440 -5.43% 16,799
26-09-29 US$2.580 +2.79% 15,567
26-09-28 US$2.510 -5.99% 53,048

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JUNS Stock